MX2020003620A - Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida. - Google Patents

Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.

Info

Publication number
MX2020003620A
MX2020003620A MX2020003620A MX2020003620A MX2020003620A MX 2020003620 A MX2020003620 A MX 2020003620A MX 2020003620 A MX2020003620 A MX 2020003620A MX 2020003620 A MX2020003620 A MX 2020003620A MX 2020003620 A MX2020003620 A MX 2020003620A
Authority
MX
Mexico
Prior art keywords
amino
purin
carboxamide
trichloroanilino
cis
Prior art date
Application number
MX2020003620A
Other languages
English (en)
Inventor
Lianfeng Huang
Yu Pu
Scott Bone
Tracy Lee Gaebele
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2020003620A publication Critical patent/MX2020003620A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan formulaciones y formas de dosificación de cis-4-[2-{[(3S,4R)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanil ino)-9H-purin-9-il]-1-metilciclohexano-1-carboxamida, llamado de forma alternativa (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-pir an-4-il)amino)-8-((2,4,6- triclorofenil)amino)-9H-purin-9-il)-1-me tilciclohexano-1-carboxamida, 5 o una sal farmacéuticamente aceptable, tautómero, solvato, hidrato, cocristal, clatrato, o polimorfo de este.
MX2020003620A 2017-10-04 2018-10-03 Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida. MX2020003620A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762568107P 2017-10-04 2017-10-04
PCT/US2018/054151 WO2019070845A1 (en) 2017-10-04 2018-10-03 COMPOSITIONS AND METHODS OF USING CIS-4- [2 - {[(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO} -8- (2,4,6-TRICHLOROANILINO) -9H-PURINE-9 yl] -1-methylcyclohexane-1-carboxamide

Publications (1)

Publication Number Publication Date
MX2020003620A true MX2020003620A (es) 2020-10-28

Family

ID=64308792

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003620A MX2020003620A (es) 2017-10-04 2018-10-03 Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.

Country Status (13)

Country Link
US (4) US10543214B2 (es)
EP (1) EP3691687A1 (es)
JP (1) JP7287955B2 (es)
KR (1) KR20200062270A (es)
CN (1) CN111432841A (es)
AU (1) AU2018345647A1 (es)
BR (2) BR122022005778B1 (es)
CA (1) CA3078368A1 (es)
EA (1) EA202090884A1 (es)
IL (1) IL273658B2 (es)
MX (1) MX2020003620A (es)
SG (1) SG11202002864PA (es)
WO (1) WO2019070845A1 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2005063766A2 (en) 2003-12-23 2005-07-14 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
CA2604161A1 (en) * 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
EP1877042A4 (en) 2005-04-18 2011-03-02 Rubicon Res Private Ltd BIOLOGICALLY IMPROVED COMPOSITIONS
EP1951693A4 (en) 2005-11-18 2012-05-30 Astrazeneca Ab SOLID FORMULATIONS
WO2007134298A2 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
KR20150028857A (ko) 2006-10-27 2015-03-16 시그날 파마소티칼 엘엘씨 4-[9-(테트라하이드로-퓨란-3-일)-8-(2,4,6-트리플루오로-페닐아미노)-9ｈ-퓨린-2-일아미노]-사이클로헥산-1-올을포함하는 고체 형태들, 이들의 조성물들 및 이들의 용도
PT2279731E (pt) 2008-04-23 2013-08-30 Farmasierra Mfg S L Composição farmacêutica melhorada contendo ibuprofeno e codeína
US20100135855A1 (en) * 2008-11-26 2010-06-03 Koninklijke Philips Electronics N.V. Method for depositing substances on a support
TWI410418B (zh) * 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
US20160074399A1 (en) * 2013-05-06 2016-03-17 Clovis Oncology, Inc. Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
US9637487B2 (en) * 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2980464T3 (es) * 2014-10-06 2024-10-01 Signal Pharm Llc Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
HUE056631T2 (hu) 2016-04-01 2022-02-28 Signal Pharm Llc (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik

Also Published As

Publication number Publication date
US11701362B2 (en) 2023-07-18
US20210128564A1 (en) 2021-05-06
US10898488B2 (en) 2021-01-26
WO2019070845A1 (en) 2019-04-11
US20200113908A1 (en) 2020-04-16
BR112020006599A2 (pt) 2020-10-06
JP2020536868A (ja) 2020-12-17
US10653697B2 (en) 2020-05-19
IL273658B1 (en) 2024-06-01
AU2018345647A1 (en) 2020-04-16
US10543214B2 (en) 2020-01-28
US20190099425A1 (en) 2019-04-04
CN111432841A (zh) 2020-07-17
IL273658A (en) 2020-05-31
JP7287955B2 (ja) 2023-06-06
BR112020006599B1 (pt) 2024-02-20
CA3078368A1 (en) 2019-04-11
IL273658B2 (en) 2024-10-01
SG11202002864PA (en) 2020-04-29
US20200237767A1 (en) 2020-07-30
EA202090884A1 (ru) 2020-06-26
EP3691687A1 (en) 2020-08-12
BR122022005778B1 (pt) 2024-01-09
KR20200062270A (ko) 2020-06-03

Similar Documents

Publication Publication Date Title
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
MX2017007748A (es) Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk).
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
UY38296A (es) Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
PH12016501344A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
WO2016168682A3 (en) Bromodomain inhibitor
CL2019003857A1 (es) Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas.
CN106536480A8 (zh) 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
MX2021009764A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
EP3807279A4 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
WO2016141296A8 (en) Tricyclic kinase inhibitors of melk and methods of use
ECSP18051143A (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
TN2015000445A1 (en) Derivatives of dolastatin 10 and auristatins
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
EP3974441A4 (en) NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
MY193239A (en) Novel b-lactamase inhibitors